Vaxcyte (PCVX) Free Cash Flow (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Free Cash Flow data on file, last reported at -$287.0 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$287.0 million, down 68.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$779.9 million (down 65.53% YoY), and the FY2025 annual result was -$663.1 million, down 42.36% from the prior year.
• Free Cash Flow retreated to -$287.0 million in Q1 2026 per PCVX's latest filing, from -$226.8 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$30.6 million in Q1 2022 and troughed at -$287.0 million in Q1 2026.
• A 5-year average of -$112.1 million and a median of -$106.2 million in 2024 frame the typical range for Free Cash Flow.
• On a YoY basis, Free Cash Flow climbed as much as 20.8% in 2024 and fell as far as 245.16% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$66.4 million in 2022, then tumbled by 102.02% to -$134.1 million in 2023, then advanced by 20.8% to -$106.2 million in 2024, then plunged by 113.61% to -$226.8 million in 2025, then slipped by 26.53% to -$287.0 million in 2026.
• Business Quant data shows PCVX's Free Cash Flow at -$287.0 million in Q1 2026, -$226.8 million in Q4 2025, and -$145.4 million in Q3 2025.